Intellia Therapeutics, Inc.

NTLA

Exchange: Nasdaq
Industry: In Vitro & In Vivo Diagnostic Substances
SEC CIK: 0001652130

SEC filings (opens in a new tab)

In the last 90 days, Intellia Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 330 institutions reported holding it in 13F filings for Q2 2026, worth $2.43B in total; ARK Invest is the only superinvestor holding it.

Key figures

Market capClose on Nov 12, 2026: $1.48B
Insider buysOpen market, last 90 days: 0
Insider sellsLast 90 days, $417.9K in total: 3
13F holdersQ2 2026, +25 vs. previous quarter: 330
13F valueReported value at the end of Q2 2026: $2.43B
Superinvestors holdingAt the end of Q2 2026: 1

Price chart

Chart by TradingView (opens in a new tab)

Financials

See financial statements

From SEC filings, in USD.

Revenue, FY2025: $67.7M; +16.9% year over year
Net income, FY2025: -$412.7M; No comparable prior period
Free cash flow, FY2025: -$395.9M; No comparable prior period
Revenue, Q3 FY2026: $7.16M; −48.0% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $412.7M (609.9% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest: 44.4M; Shares sold short
Change: −73.5K; −0.2% vs. previous
Days to cover: 11.05; At average daily volume

Superinvestors holding NTLA, Q2 2026

Go to the superinvestors tab

1 superinvestor reports holding Intellia Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.

ARK Invest

Cathie Wood

1.9%

Intellia Therapeutics, Inc.'s share of the portfolio

Shares: 16,875,684
Value: $285.5M

Latest insider trades

See all insider trades

Open-market purchases and sales by Intellia Therapeutics, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Nov 3, 2026 (view filing)4:20 PM ET	Nov 2	1 day	Leonard John MPresident and CEO	SSale	−9.00K	$11.99	−$107.9K	−0.8%1.14M after	10b5-1
Oct 6, 2026 (view filing)4:05 PM ET	Oct 2	4 days	Dube Michael PVP, Chief Accounting Officer	SSale	−1.86K	$12.43	−$23.2K	−2.8%65.0K after
Aug 24, 2026 (view filing)4:05 PM ET	Aug 20-21	4 days	Leonard John MPresident and CEO	SSale	−22.7K	$12.65	−$286.8K	−1.9%1.15M after	2 lots10b5-1
Jul 24, 2026 (view filing)5:26 PM ET	Jul 22	2 days	Dulac Edward J IIIEVP, Chief Financial Officer	SSale	−8.11K	$11.25	−$91.2K	−5.2%148.2K after
Jul 6, 2026 (view filing)5:02 PM ET	Jul 1	5 days	Dube Michael PVP, Chief Accounting Officer	SSale	−2.64K	$16.78	−$44.3K	−3.8%66.9K after
Jul 6, 2026 (view filing)5:01 PM ET	Jul 2	4 days	Dulac Edward J IIIEVP, Chief Financial Officer	SSale	−4.68K	$18.00	−$84.2K	−2.9%156.3K after	10b5-1
Mar 3, 2026 (view filing)	Mar 2	1 day	Basta JamesEVP, General Counsel	SSale	−1.21K	$13.78	−$16.7K	−0.8%156.8K after
Mar 3, 2026 (view filing)	Mar 2	1 day	Clark ElianaEVP, Chief Technical Officer	SSale	−607	$13.78	−$8.36K	−0.6%93.9K after
Jan 7, 2026 (view filing)	Jan 5	2 days	Leonard John MPresident and CEO	SSale	−34.1K	$9.21	−$314.5K	−3.3%1.01M after
Jan 7, 2026 (view filing)	Jan 5	2 days	Schultes Birgit CEVP, Chief Scientific Officer	SSale	−8.51K	$9.21	−$78.4K	−7.9%98.5K after

Top 10 13F holders, Q2 2026

See all 330 holders

The largest institutional positions in Intellia Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding NTLA in Q2 2026
Institution	Shares	Value	% of portfolio	Change in shares	Action
ARK Investment Management LLCSuperinvestorARK Invest	16,875,684	$285.5M	1.85%	+2,366,437+16.3%	Added
BlackRock, Inc.	15,409,023	$260.7M	0.00%	+3,253,217+26.8%	Added
State Street Corp	9,234,987	$156.3M	0.00%	+2,312,311+33.4%	Added
Vanguard Portfolio Management LLC	7,332,401	$124.1M	0.01%	+1,109,076+17.8%	Added
D. E. Shaw & Co., Inc.	6,443,323	$109.0M	0.07%	+715,146+12.5%	Added
Vanguard Capital Management LLC	6,028,586	$102.0M	0.00%	+944,481+18.6%	Added
Two Sigma Investments, LP	5,235,348	$88.6M	0.07%	+529,447+11.3%	Added
FMR LLC	4,773,034	$80.8M	0.00%	+2,705,812+130.9%	Added
Ra Capital Management, L.P.	4,526,926	$76.6M	0.67%	+4,526,926	New
Regeneron Pharmaceuticals, Inc.	3,702,995	$62.7M	35.35%	00.0%	Unchanged

Holders of 5% or more of NTLA

See all 5 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Intellia Therapeutics, Inc..

Largest holders of NTLA from 13D and 13G filings
Holder	Latest form	Stake	Change	First filed	Latest filing	Filing
ARK Investment Management LLCSuperinvestorARK Invest	13G/A	12.27%14.2M shares	+1.17 ppfrom 11.10%	Feb 16, 20217 filings	Feb 3, 2026	SEC
BlackRock, Inc.	13G/A	8.20%8.45M shares	–	Apr 17, 20251 filing	Apr 17, 2025	SEC
State Street Corp	13G	5.60%7.81M shares	−1.20 ppfrom 6.80%	Jan 24, 20245 filings	Nov 10, 2026	SEC
Vanguard Portfolio Management LLC	13G	5.30%6.27M shares	New	Apr 29, 20261 filing	Apr 29, 2026	SEC
Vanguard Capital Management LLC	13G	5.03%5.95M shares	New	Apr 30, 20261 filing	Apr 30, 2026	SEC

Politician trades

All politician trades in NTLA

2 members of Congress reported 12 trades in Intellia Therapeutics, Inc. since 2020. Newest filings:

Latest politician trades in NTLA
Filed	Politician	Type	Amount
Sep 5, 2023	Thomas R. Carper Senate · DE	Sell (full)	$1K-$15K
Jun 30, 2023	Thomas R. Carper Senate · DE	Buy	$1K-$15K
Mar 3, 2022	Donald S. Beyer, Jr. House · VA	Sell	$15K-$50K
Oct 30, 2021	Donald S. Beyer, Jr. House · VA	Sell	$1K-$15K
Oct 1, 2021	Donald S. Beyer, Jr. House · VA	Sell	$1K-$15K

Thomas R. Carper
Senate · DE · Sep 5, 2023
Sell (full)$1K-$15K
Thomas R. Carper
Senate · DE · Jun 30, 2023
Buy$1K-$15K
Donald S. Beyer, Jr.
House · VA · Mar 3, 2022
Sell$15K-$50K
Donald S. Beyer, Jr.
House · VA · Oct 30, 2021
Sell$1K-$15K
Donald S. Beyer, Jr.
House · VA · Oct 1, 2021
Sell$1K-$15K